Venture capital fund · 2 deals
Austin
Every published round Santé Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Santé Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Glyscend | 12 Jun 2020, Series A | 1 | 1 | |
| Glyscend, Inc. | Oral polymer drugs mimicking bariatric surgery for metabolic disease | Jun 2020, Series A | 1 | 1 |
Fund closes reported for Santé Ventures, as distinct from the investments it has made.
Companies Santé Ventures has backed that another company then bought. An exit for the holding, not a deal Santé Ventures did.
Stories naming Santé Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio